Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), will terminate its strategic collaboration and licensing agreement with Adaptive Biotechnologies, originally valued at up to USD 2 billion. According to a U.S. Securities and Exchange Commission (SEC) document disclosed on August 18, the partnership will officially end on February 9, 2026.
Partnership Background
The collaboration between Genentech and Adaptive Biotechnologies began in January 2019. The goal was to leverage Adaptive’s T-cell receptor (TCR) discovery platform, TruTCR, to develop personalized T-cell therapies for various cancers. Adaptive received an upfront payment of USD 300 million and had the potential to earn up to USD 1.7 billion in milestone payments.
Termination Reason
A Genentech spokesperson stated that the decision to terminate the collaboration was not due to safety concerns but was a prudent consideration based on strategic adjustments. Adaptive responded that it will continue to advance its TCR discovery platform and explore other immunological applications and partnership opportunities.-Fineline Info & Tech
